Amendments to and Listing of the Claims:

1. to 6. (Cancelled)

7. (Previously presented) A composition as claimed in claim 34, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

8. to 14. (Cancelled)

15. to 19. (Cancelled)

20. (Previously Presented) A method of treating a patient in need of treatment with fexofenadine or a pharmaceutically acceptable salt thereof which comprises administering an effective amount of a composition according to claim 34 to an eye or nose of a patient in need of such treatment.

21. (Previously Presented) A method of treating rhinitis which comprises administering an effective amount of a composition according to claim 34, to an eye or nose of a patient in need of such treatment.

22. to 27. (Cancelled)

28. (Currently amended) The composition as claimed in claim 34, ~~which further comprises~~ containing a gelling agent or a bioadhesive material.

29. (Previously presented) The composition as claimed in claim 28, wherein the gelling agent or bioadhesive material is selected from the group consisting of pectin, alginate, starch, gellan, chitosan, and a block co-polymer.

30. (Previously presented) The composition as claimed in claim 35, which further comprises a material that provides for controlled release of the fexofenadine or a pharmaceutically acceptable salt thereof.

31. (Previously Presented) A method of treating a patient in need of a treatment with fexofenadine or a pharmaceutically acceptable salt thereof, the method comprising administering an effective amount of the composition according to claim 35 to an eye or nose of a patient in need of such treatment.

32. (Previously Presented) A method of treating rhinitis, the method comprising administering an effective amount of a composition according to claim 35 to an eye or nose of a patient in need of such treatment.

33. (Previously presented) A method of treating a patient with a controlled release dose of fexofenadine or a pharmaceutically acceptable salt thereof, the method comprising administering an effective amount of a composition according to claim 30 to a patient in need of such treatment.

34. (Currently Amended) A composition consisting essentially of

(i) fexofenadine or a pharmaceutically acceptable salt thereof and

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, and glycofurol, and

(iii) optionally, a gelling agent or a bioadhesive material,

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye or nose.

35. (Previously presented) A composition comprising

(i) fexofenadine or a pharmaceutically acceptable salt thereof in an amount selected from the group consisting of 100 μg/ml to 100 mg/ml and 0.5% to 40% wt/wt and

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, and glycofurol,

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye or nose.

36. (Previously presented) The composition of claim 35, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

37. (Previously presented) The composition of claim 35, wherein the composition further comprises an aqueous vehicle.

38. (Previously presented) The composition of claim 28, wherein the gelling agent or bioadhesive material is a polysaccharide.

39. (Currently amended) The composition of claim 29, wherein the block co-polymer is a poloxamer.

40. (Currently amended) An aqueous composition consisting essentially of

(i) fexofenadine or a pharmaceutically acceptable salt thereof;

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, ~~propylene glycol,~~ and glycofurol, and

(iii) an aqueous vehicle

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye or nose.

41. (Currently amended) An aqueous composition comprising

(i) fexofenadine or a pharmaceutically acceptable salt thereof in an amount selected from the group consisting of 100 μg/ml to 100 mg/ml and 0.5% to 40% wt/wt,

(ii) a pharmaceutical excipient that increases the solubility of the fexofenadine or salt in water selected from the group consisting of a cyclodextrin, ~~propylene glycol,~~ and glycofurol, and

(iii) an aqueous vehicle

which composition is adapted for delivery of the fexofenadine or pharmaceutically acceptable salt thereof to the eye or nose.

42. (Previously presented) The composition of claim 40, wherein the concentration of the pharmaceutical excipient (ii) is 0.5 to 50% w/v.

43. (Previously presented) The composition of claim 41, wherein the concentration of the pharmaceutical excipient (ii) is 0.5 to 50% w/v.

44. (Previously presented) The composition of claim 34, wherein the composition is in the form of a powder formulation and the pharmaceutical excipient (ii) is a cyclodextrin.

45. (Previously presented) The composition of claim 44, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

46. (Previously presented) The composition of claim 35, wherein the composition is in the form of a powder formulation and the pharmaceutical excipient (ii) is a cyclodextrin.

47. (Previously presented) The composition of claim 45, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

48. (Previously presented) The composition according to claim 40, wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin.

49. (Previously presented) A method of treating a patient in need of treatment with fexofenadine or a pharmaceutically acceptable salt thereof comprising administering an effective amount of a composition of claim 40 to an eye or nose of the patient.

50. (Previously presented) A method of treating rhinitis comprising administering an effective amount of a composition of claim 40 to an eye or nose of the patient.

51. (Previously presented) The composition of claim 40, further comprising a gelling agent or a bioadhesive material.

52. (Previously presented) The composition of claim 41, wherein the gelling agent or bioadhesive material is selected from the group consisting of pectin, alginate, starch, gellan, chitosan, and a block co-polymer.

53. (Previously presented) The composition of claim 41, further comprising a material that provides for controlled release of the fexofenadine or pharmaceutically acceptable salt thereof.

54. (Previously presented) A method of treating a patient in need of a treatment with fexofenadine or a pharmaceutically acceptable salt thereof comprising administering an effective amount of the composition of claim 41 to an eye or nose of the patient.

55. (Previously presented) A method of treating rhinitis comprising administering an effective amount of a composition of claim 41 to an eye or nose of the patient.

56. (Previously presented) A method of treating a patient with a controlled release dose of fexofenadine or a pharmaceutically acceptable salt thereof comprising administering an effective amount of a composition of claim 53 to the patient.

57. (Previously presented) The composition of claim 51, wherein the gelling agent or bioadhesive material is a polysaccharide.

58. (Previously presented) The composition of claim 52, wherein the block co-polymer is a poloxamer.